An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

Launched by ZHI-HONG LIU, M.D. · Jan 3, 2011

Keywords

ClinConnect Summary

To access the efficacy and safety of MMF compared to corticosteroid in in treatment of proliferative IgA Nephropathy(IgAN).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who signed written informed consent form
• • 2. age between 18-60 years, female or male
• • 3. diagnosed IgA Nephropathy (IgAN) by renal biopsy during 1 months
• • 4. renal biopsy had: 10%\< crescents\<50%; endocapillary hypercellularity; or necrosis ,and interstitial fibrosis\<50%,
• • 5. proteinuria\>1g/24h for two times
• Exclusion Criteria:
• • 1. secondary IgA Nephropathy (IgAN);
• • 2. eGFR\<30ml/min/1.73m2.( MDRD formula)
• • 3. liver disfunction;
• • 4. uncontrolled hypertension
• • 5. WBC \<3000/mm3
• • 6. Severe viral infection(HBV, HCV, CMV) within 3 months ofor known HIV infection.
• • 7. diabetes or obesity(BMI\>28) ;
• • 8. severe infection or central nervous system symptoms.